Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies

Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies

Purpose The receptor tyrosine kinase rearranged during transfection (RET) can be oncogenically activated by gene fusions or point mutations. Multikinase inhibitors such as cabozantinib, lenvatinib and vandetanib have demonstrated activity in RET-dependent malignancies, and selective RET inhibitors (...

Full description

Bibliographic Details
Main Authors: Jessica Lee, Vivek Subbiah, Shuang Liu, Jason Roszik, David Hong, Funda Meric-Bernstam, John Heymach, Ramona Dadu, Kenneth Hess, Le Huang, Aparna Hegde, Alexander Y Andreev-Drakhlin, Maria Cabanillas, Mimi I Hu, Naifa L Busaidy, Steven I Sherman, Elizabeth G Grubbs, Siraj M Ali, Yasir Y Elamin, George R Simon, George R Blumenschein, Jr, Vassiliki A Papadimitrakopoulou
Format: Article
Language:English
Published: Elsevier 2020-10-01
Series:ESMO Open
Online Access:https://esmoopen.bmj.com/content/5/5/e000799.full

Internet

https://esmoopen.bmj.com/content/5/5/e000799.full

Similar Items